Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Angeion

This article was originally published in The Gray Sheet

Executive Summary

Angeion: Company gains investigational device exemption for clinical studies of its Model 2020 and 2022 implantable cardioverter defibrillators at 35 centers in the U.S. and plans to commence U.S. trials "in a few weeks," company Chairman and CEO Whitney McFarlin reports at a Feb. 5 session of the Piper Jaffray medical device conference in New York City. The 2020, with a weight of 89 grams and volume of 47 cc, is 25% smaller than the firm's 110 gram, 60 cc Sentinel series ICD, for which a June 1997 premarket approval application is pending at FDA ("The Gray Sheet" June 23, In Brief). The 2020 family and Sentinel feature small cap, Tuned biphasic waveform and the ASEC II dual battery system. The 2020 family also offers 60 minutes of electrogram storage. The 2022 model is specifically intended as a replacement device compatible with other manufacturers' lead systems. The devices will be marketed in the U.S. through Angellan Medical Systems' 100-person direct sales force. Angellan is a 50/50 joint venture established by Angeion and Synthelabo's Ela Medical unit. McFarlin also tells investors that Angeion is developing a model 2030 single chamber ICD and a 2100 dual-chamber ICD, for which clinical trials will begin in 1998 and 1999, respectively...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel